Genezen, a gene and cell therapy contract development and manufacturing organisation (CDMO), announced on Monday that it has named Steven J. Favaloro as its new president and chief executive officer (CEO).

Favaloro has experience in gene and cell therapy, on both the innovator and CDMO side. He has served in executive positions at Arbor Biotechnologies, Arranta Bio and Brammer Bio.

Bill Vincent, Founder and Executive Chairman of Genezen, said: "Steve's track record in the CDMO market - particularly in viral vector and cell and gene therapy companies - speaks for itself and will be extraordinarily valuable in spearheading Genezen's ambitious growth plan. We know that 2023 will be a pivotal year for the company, and with Steve's experience and vision, there is tremendous confidence that we will achieve our goal to be a leading choice of CDMO in this sector."